Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review

• Katsuyuki Hotta ,

  * E-mail: khotta@md.okayama-u.ac.jp

  Affiliations Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan, Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯
• Yuka Kato,

  Affiliation Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯
• Natasha Leighl,

  Affiliation Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Hospital Division and the University of Toronto, Toronto, Ontario, Canada

  ⨯
• Nagio Takigawa,

  Affiliation Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan

  ⨯
• Rabab Mohamed Gaafar,

  Affiliation National Cancer Institute, Cairo University, Cairo, Egypt

  ⨯
• Hiroe Kayatani,

  Affiliation Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯
• Taizo Hirata,

  Affiliation Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯
• Kadoaki Ohashi,

  Affiliation Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯
• Toshio Kubo,

  Affiliation Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯
• Masahiro Tabata,

  Affiliation Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯
• Mitsune Tanimoto,

  Affiliation Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan

  ⨯
• Katsuyuki Kiura

  Affiliation Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan

  ⨯